KROS
Keros Therapeutics Inc
NASDAQ · Biotechnology
$17.57
+0.33 (+1.91%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 2.89M | 5.15M | 97.48M | 103.26M | 79.84M |
| Net Income | -152,464,386 | -244,551,679 | -15,590,568 | -15,524,708 | -13,846,639 |
| EPS | — | — | — | — | — |
| Profit Margin | -5,277.6% | -5,013.7% | -16.0% | -15.0% | -17.3% |
| Rev Growth | -43.9% | -43.9% | -0.3% | +11.8% | -2.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 225.62M | 173.40M | 194.80M |
| Total Equity | — | — | 400.53M | 374.54M | 364.51M |
| D/E Ratio | — | — | 0.56 | 0.46 | 0.53 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -170,341,874 | -288,406,309 | -19,293,481 | -22,220,211 | -17,087,554 |
| Free Cash Flow | — | — | -15,397,530 | -17,331,210 | -15,756,938 |